Galleri is a blood test that aims to detect over 50 types of cancer early. It analyzes cell-free DNA (cfDNA) and methylation patterns to identify potential cancer signals. The test is intended for ...
MOBILE, Ala. (WALA) - As the second leading cause of death in the U.S., 1 cancer remains a major public health crisis. Early detection and diagnosis of cancer have been proven to significantly improve ...
In January 2022, Anthony Arenz, a 51-year-old living in Mesa, Arizona, breathed a small sigh of relief. The Galleri blood test, which screens for 50 types of cancer, hadn't detected any positive signs ...
The Galleri test requires a prescription from a licensed health care provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific ...
GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.) The integration will help streamline the process of ordering the Galleri test ...
MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with ...
First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket ...
Galleri Accurately Predicted the Location of the Cancer in Almost All Cases Initially Considered as False Positives, Reinforcing the Value of Galleri's CSO Capability MENLO PARK, Calif. and OXFORD, ...
CANTON, Mass. & MENLO PARK, Calif.--(BUSINESS WIRE)-- Point32Health, the parent company of Harvard Pilgrim Health Care, and GRAIL, LLC, a health care company with a mission of detecting cancer early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback